Tyrosine kinase inhibitor (TKI) level of resistance and development to blast turmoil (BC), both linked to persistent -catenin activation, remain formidable problems for chronic myeloid leukemia (CML). with nilotinib by itself, considerably impaired their engraftment potential in NOD/SCID/IL2R-null-3/GM/SF mice and considerably prolonged success. Our data recommend potential advantage of concomitant -catenin and BcrCAbl inhibition to… Continue reading Tyrosine kinase inhibitor (TKI) level of resistance and development to blast